Lenzilumab (KB 003) is a humanized monoclonal antibody targeting CSF2/GM-CSF, with applications in COVID-19 treatment and research on chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) [1] [2].
CAS Number:
[1229575-09-0]
* VAT and and shipping costs not included. Errors and price changes excepted